BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesCompany update

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Eiry W. Roberts, M.D., who previously served as Neurocrine's Chief Medical Officer and currently serves as a Strategic Advisor, will rejoin the Company's executive management team as Chief

Related news

NBIXNeurocrine Biosciences2026-07-21 20:05 EST

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

ANVSAnnovis Bio2026-07-01 12:00 EST

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

ECORelectroCore2026-09-09 12:00 EST

electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

BCLIBrainstorm Cell Therapeutics Inc.2026-07-28 12:00 EST

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

VKTXViking Therapeutics2026-07-23 11:05 EST

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

TNXPTonix Pharmaceuticals2026-09-08 11:00 EST

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

NBIXNeurocrine Biosciences2026-09-28 20:05 EST

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Stock data

Close
140.71 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States